Mesh Bio, a Singapore-based health deep tech startup transforming chronic disease management through predictive analytics, has raised $3.5 million in Series A financing led by East Ventures, a pioneering and leading sector-agnostic venture capital firm focusing on Southeast Asia. This round of investment also saw participation of Elev8, Seed Capitals, and other existing shareholders.

The funding will allow Mesh Bio to offer its digital twin technologies to healthcare providers and scale the deployment of these solutions across Hong Kong and Southeast Asia, mainly Indonesia and the Philippines. 

This new investment comes three months after Mesh Bio secured historic regulatory approval and an implementation pilot with public health systems for one of its digital twin technologies in Singapore, which represents a major opportunity to improve patient outcomes from chronic diseases.

In October 2023, it received approval from Singapore’s Health Sciences Authority (HSA) to market its HealthVector Diabetes as a Software Medical Device (SaMD). HealthVector Diabetes is currently used in an implementation pilot at Singapore General Hospital (SGH), Tan Tock Seng Hospital (TTSH), and selected polyclinics for potential clinical adoption.

The company’s DARA Health Intelligence Platform, enables data-driven care delivery, which improves patient engagement and health outcomes, has been used by more than 120 medical centers across Singapore, Malaysia, and Indonesia for preventive health screening. Mesh Bio has expanded the platform to chronic disease management with HealthVector Diabetes.